eBook: Antibody-Drug Conjugates — A Technology UpdateeBook: Antibody-Drug Conjugates — A Technology Update

The first generation of antibody–drug candidates (ADCs) suffered from instability and systemic drug loss with resulting toxicity. Second-generation ADCs used more potent targeting agents and improved linker chemistries. The third generation introduced site-specific conjugation to produce homogenous ADCs with well-defined drug:antibody ratios (DARs). Now, companies are presenting fourth-generation concepts with new linkers, dual payloads, and bispecific antibodies to expand the modality even farther. This eBook provides a glimpse into the latest technological advances in ADC development.

First, BPI editor in chief Cheryl Scott presents a curated collection of reporting from the BioProcess Insider tracking movements among partners and service providers that indicate strong interest in next-generation approaches to ADC research and development. Next, the global vice president for chemical development operations at Veranova examines three factors — stability, solubility, and efficiency of payload release — that determine the role that linkers play in ADC development. He offers insight into optimizing linker selection, ensuring stability, and contributing to the overall success of these groundbreaking therapies. And finally, BPI’s managing editor discusses ADC targeting based on silicon chemistry with the chief medical and scientific officer at OS Therapies.

Register or Login and hit Download to get the full eBook.